Aptinyx: Rises on restarting trial of co's nerve damage treatment

Aptinyx

04/01/2021 14:03

** Shares of drug developer  APTX.O  rise 1.4% to $3.51
premarket
    ** Co says it has recommenced mid-stage trial of its
experimental drug, NYX-2925, in patients with nerve damage
caused by diabetes  urn:newsml:reuters.com:*:nBw7SrzzKa
    ** Study had been suspended due to escalation of COVID-19
pandemic in U.S. 
    ** Trial to enroll approximately 200 patients
    ** Aptinyx anticipates reporting data from study in H1 2022

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))